tbuckley/cabot-search huggingface dataset:
FP14.08 Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021
Authors: J. Neal, F. Lim, E. Felip, R. Gentzler, S. Patel, J. Baranda, B. Fang, C. Squillante, M. Simonelli, S. Werneke, D. Curran, S. Ponce Aix
Journal: Journal of Thoracic Oncology (2021)
FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).
Authors: K. Goto, J. Wolf, Y. Elamin, F. Santini, V. Soldatenkova, A. Sashegyi, A. Bence Lin, B. Lin, S. Novello, E. Arriola Aperribay, M. Perol, H. Loong, A. Drilon, K. Park, B. Solomon, C. Zhou
Journal: Journal of Thoracic Oncology (2021)
P35.15 Molecular Epidemiology of KRAS G12C Mutations in Chinese Lung Cancer Patients
Authors: H. Loong, N. Du, C. Cheng, H. Lin, J. Guo, G. Lin, M. Li, T. Jiang, Z. Shi, Y. Cui, X. Jin, J. Yao, Y. Xing, M. Yao, K. Wang, T. Mok, L. Liu
Journal: Journal of Thoracic Oncology (2021)
Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia
Authors: Misbah Sabir, Monica Hellesoy, Jarno Kivioja, Caroline Engen, Claire Amiable, Mihaela Popa, Remi Guillon, Øystein Bruserud, Caroline A Heckman, Emmet McCormack, Dominique Surleraux, Bjørn Tore Gjertsen
Journal: Blood (2017)
P76.49 The Impact of Baseline Systemic Inflammatory Status Parameters in Patients Treated with EGFR-Tyrosine Kinase Inhibitors
Authors: P. Martin, M. Barr, A.M. Baird, S. Halliday, B. Hayes, S. Cuffe, L. Coate, S. Gray, S. Finn
Journal: Journal of Thoracic Oncology (2021)
Gibberellin‐regulated protein sensitization in Japanese cedar (<i>Cryptomeria japonica</i>) pollen allergic Japanese cohorts
Authors: Tomona Iizuka, Mari Takei, Yukiko Saito, Farhana Rumi, Jingkang Zheng, Xiaoshuang Lu, Philippe Chafey, Cédric Broussard, Laurence Guilloux‐Assalet, Denis Charpin, Motohiro Ebisawa, Hélène Sénéchal, Tomoyasu Aizawa, Pascal Poncet
Journal: Allergy (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Human-induced pluripotent stem cells in cardiovascular research: current approaches in cardiac differentiation, maturation strategies, and scalable production
Authors: Dilip Thomas, Nathan J Cunningham, Sushma Shenoy, Joseph C Wu
Journal: Cardiovascular Research (2021)

Manifestations of cardiovascular diseases (CVDs) in a patient or a population differ based on inherent biological makeup, lifestyle, and exposure to environmental risk factors. These variables mean that therapeutic interventions may not provide the same benefit to every patient. In the context of CVDs, human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) offer an opportunity to model CVDs in a patient-specific manner. From a pharmacological perspective, iPSC-CM models can serve as go/no-go tests to evaluate drug safety. To develop personalized therapies for early diagnosis and treatment, human-relevant disease models are essential. Hence, to implement and leverage the utility of iPSC-CMs for large-scale treatment or drug discovery, it is critical to (i) carefully evaluate the relevant limitations of iPSC-CM differentiations, (ii) establish quality standards for defining the state of cell maturity, and (iii) employ techniques that allow scalability and throughput with minimal batch-to-batch variability. In this review, we briefly describe progress made with iPSC-CMs in disease modelling and pharmacological testing, as well as current iPSC-CM maturation techniques. Finally, we discuss current platforms for large-scale manufacturing of iPSC-CMs that will enable high-throughput drug screening applications.
P72.05 From OR to Lab: Optimized Protocol for Functional Immune Profiling of Freshly Resected Human Non-Small Cell Lung Carcinoma (NSCLC) Specimens
Authors: S. Alarcon, H. Vo, M. Noureddine, B. Piel, J. Duke-Cohan, B. Reinhold, C. Lathan, E. Reinherz, D. Barbie, C. Paweletz, E. Ivanova, J. Wain
Journal: Journal of Thoracic Oncology (2021)
The Role of the Medial Prefrontal Cortex in Moderating Neural Representations of Self and Other in Primates
Authors: Masaki Isoda
Journal: Annual Review of Neuroscience (2021)

As a frontal node in the primate social brain, the medial prefrontal cortex (MPFC) plays a critical role in coordinating one's own behavior with respect to that of others. Current literature demonstrates that single neurons in the MPFC encode behavior-related variables such as intentions, actions, and rewards, specifically for self and other, and that the MPFC comes into play when reflecting upon oneself and others. The social moderator account of MPFC function can explain maladaptive social cognition in people with autism spectrum disorder, which tips the balance in favor of self-centered perspectives rather than taking into consideration the perspective of others. Several strands of evidence suggest a hypothesis that the MPFC represents different other mental models, depending on the context at hand, to better predict others’ emotions and behaviors. This hypothesis also accounts for aberrant MPFC activity in autistic individuals while they are mentalizing others.
The dark side of the gut: Virome–host interactions in intestinal homeostasis and disease
Authors: Yuhao Li, Scott A. Handley, Megan T. Baldridge
Journal: The Journal of Experimental Medicine (2021)

The diverse enteric viral communities that infect microbes and the animal host collectively constitute the gut virome. Although recent advances in sequencing and analysis of metaviromes have revealed the complexity of the virome and facilitated discovery of new viruses, our understanding of the enteric virome is still incomplete. Recent studies have uncovered how virome-host interactions can contribute to beneficial or detrimental outcomes for the host. Understanding the complex interactions between enteric viruses and the intestinal immune system is a prerequisite for elucidating their role in intestinal diseases. In this review, we provide an overview of the enteric virome composition and summarize recent findings about how enteric viruses are sensed by and, in turn, modulate host immune responses during homeostasis and disease.
Tricuspid Anatomic Regurgitant Orifice Area by Functional DSCT
Authors: Bernardo B.C. Lopes, Paul Sorajja, Go Hashimoto, Miho Fukui, Vinayak N. Bapat, Yu Du, Richard Bae, Robert S. Schwartz, Larissa I. Stanberry, Maurice Enriquez-Sarano, Santiago A. Garcia, John R. Lesser, João L. Cavalcante
Journal: JACC. Cardiovascular imaging (2021)
A tribute to John G. Bartlett, MD (1937–2021)
Authors: Thomas C. Quinn, Joel N. Blankson
Journal: Journal of Clinical Investigation (2021)

A true giant in the field of infectious diseases and HIV/AIDS care, John G. Bartlett, MD, passed away on January 19, 2021 (Figure 1).His absence will be felt by many, and he has left an indelible mark on the field of infectious diseases for many years to come.Known for his round-the-clock work ethic, starting at 4 am and working late into the evening, John had a grasp for what was important and timely in our field.He is well known for his early discovery of Clostridium difficile as the cause of antibiotic-associated colitis, his insights and treatment of anaerobic abdominal and pulmonary infections, community-acquired pneumonia, bioterrorism, and emerging and reemerging infectious agents, from anthrax to Zika.At Johns Hopkins, John will always be known best for his work in the HIV/AIDS field.He was the driving force for creating a dedicated HIV inpatient ward and an HIV/hepatitis outpatient clinic, which has now been named after him as the John G. Bartlett Specialty Clinic, known for providing the best care for patients with HIV and hepatitis infections.John was born in Syracuse, New York, on February 12, 1937.He attended and graduated from Dartmouth College in 1959, and obtained his medical degree in 1963 from the State University of New York (SUNY) College of Medicine in Syracuse.He pursued training in internal med-
Abstract 115: Compliant Mattresses Adversely Affect CPR Quality
Authors: Carolyn L Cason, Cynthia A Trowbridge, Sonam Marwaha, Mark D Ricard
Journal: Circulation (2010)

Background: In-hospital resuscitations are often conducted on a compliant mattress which deforms with chest compressions. Loss of CPR quality, specifically depth of compressions, is known to occur;...
Safety ofâ¯theâ¯firstâ¯dose ofâ¯mRNA SARS-CoV-2â¯vaccines inâ¯patients with rheumatic and musculoskeletal diseases.
Authors: Caoilfhionn M Connolly, Jake A Ruddy, Brian J Boyarsky, Robin K Avery, William A Werbel, Dorry L Segev, Jacqueline Garonzik-Wang, Julie J Paik
Journal: Annals of the Rheumatic Diseases (2021)
Hirschsprung disease and more: dysregulation of ERBB2 and ERBB3
Authors: Michael D. Gershon
Journal: Journal of Clinical Investigation (2021)

The enteric nervous system mediates reflexes independently of the brain and spinal cord and transmits signals bidirectionally between the gut and the brain. Hirschsprung disease and chronic intestinal pseudo-obstruction (CIPO) and pediatric CIPO are examples of congenital defects that impair gastrointestinal motility. In this issue of the JCI, Thuy-Linh Le et al. analyzed eight patients with defects in tissue that arose from the neural crest. The patients carried homozygous or heterozygous variants in ERBB3 or ERBB2, which encode transmembrane epidermal growth factor receptors that bind neuroregulin 1 (NRG1). Notably, the genetic variants resulted in loss of function with decreased expression or aberrant phosphorylation of the ERBB3/ERBB2 receptors. Experiments using mice revealed that Erbb3 and Erbb2 were expressed in enteric neuronal progenitor cells. This study is an outstanding example of descriptive observation that begs for mechanistic exploration to reveal precisely how the NRG1/ERBB3/ERBB2 pathway influences ENS development.
Abstract 1900: Cardiovascular Complications of Lower Extremity Bypass Surgery for Critical Limb Ischemia: Risk Factors and Outcomes
Authors: Louis L Nguyen, Soma Brahmanandam, Joshua A Beckman, Dennis F Bandyk, Michael Belkin, Alexander W Clowes, Gregory L Moneta, Michael S Conte
Journal: Circulation (2006)

Objectives Patients with critical limb ischemia (CLI) requiring infrainguinal bypass (IB) for limb salvage are at high risk for cardiovascular complications (CVC), which incur significant morbidity...
ヒトプロテオミクス老化研究の系統的レビューと分析は,新しいプロテオミクス老化時計を明らかにし,年齢により変化する鍵となるプロセスを同定する【JST・京大機械翻訳】
Authors: A Johnson Adiv, N Shokhirev Maxim, Wyss-Coray Tony, Lehallier Benoit
Journal: Ageing Research Reviews (2020)
Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination
Authors: Venkata Viswanadh Edara, William H. Hudson, Xuping Xie, Rafi Ahmed, Mehul S. Suthar
Journal: JAMA (2021)

Change in Donor Characteristics and Antibodies to SARS-CoV-2 in Donated Blood in the US, June-August 2020
“Corrections to Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC”
Authors: J.J. Knox, C.H. Barrios, T.M. Kim, T. Cosgriff, V. Srimuninnimit, K. Pittman, R. Sabbatini, S.Y. Rha, T.W. Flaig, R.D. Page, J.T. Beck, F. Cheung, S. Yadav, P. Patel, L. Geoffrois, J. Niolat, N. Berkowitz, M. Marker, D. Chen, R.J. Motzer
Journal: Annals of Oncology (2018)

Ann Oncol 2017; 28: 1339–1345 (doi: 10.1093/annonc/mdx075) In the original article, Figure 2B incorrectly described the curves as PFS, while it should have read OS. This has now been corrected. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCCAnnals of OncologyVol. 28Issue 6PreviewRECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points. Full-Text PDF Open Access
P69.05 Molecular and Cellular Heterogeneity Underpin Treatment Response Across a Spectrum of EGFR-Mutant Non-Small Cell Lung Cancer
Authors: J. Yuan, E. Lim, S.M. Ma, K.P. Chua, Y.F. Lee, M.J. Lim, X.H. Yeo, C. Phua, A. Takano, Z. Aung, K.H.T. Lim, E. Tan, D. Tan, G.L. Chew, W.L. Tam
Journal: Journal of Thoracic Oncology (2021)
Abstract 15055: Predictors of Mortality Among Cancer Patients Treated With Checkpoint Inhibitors
Authors: Ali M Agha, Natalie Chen, Christopher Chen, Henry Zheng, Jacob Morgan, Abir Khan, Juan Lopez-Mattei, Rohit Moudgil, Cezar Iliescu, Nicolas L Palaskas
Journal: Circulation (2019)

Introduction: Checkpoint Inhibitors are novel immunotherapeutic agents that may improve the life expectancy of cancer patients. However, they are associated with many cardiovascular complications, ...
Abstract 12622: Exploratory Analysis of Human Immunodeficiency Virus Infection Among Sudden Death Victims
Authors: Justin L Vandermolen, Mojtaba Mirzaei, Venkata Narla, Ross J Simpson
Journal: Circulation (2019)

Introduction: The risk of sudden death (SD) is higher in persons infected with HIV, although the mechanism for increased risk has not been defined. We hypothesized that psychosocial factors may imp...
Note to Self
Authors: Uzoamaka Okoro
Journal: Annals of Internal Medicine (2021)

Ad LibitumMarch 2021Note to SelfUzoamaka Okoro, MD, MScUzoamaka Okoro, MD, MScProvidence, Rhode Island (U.O.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-3003 Audio Reading - “Note to Self” Audio. Michael A. LaCombe, MD, MSc, Annals Associate Editor, reads “Note to Self” by Uzoamaka Okoro, BA Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Anhedonia and apathy competing at dusk.... Author, Article, and Disclosure InformationAffiliations: Providence, Rhode Island (U.O.)Current Author Address: Uzoamaka Okoro, MD, MSc; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Note to Self” Audio. Michael A. LaCombe, MD, MSc, Annals Associate Editor, reads “Note to Self” by Uzoamaka Okoro, BA Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics March 2021Volume 174, Issue 3Page: 414 ePublished: 16 March 2021 Issue Published: March 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Expanding the Toolbox of Adoptive Cell Immunotherapy
Authors: Nasheed M. Hossain, Patrick J. Stiff
Journal: Journal of Clinical Oncology (2021)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. January 28, 2021 ARTICLE CITATION DOI: 10.1200/JCO.21.00295 Journal of Clinical Oncology - published online before print March 25, 2021 PMID: 33764792 Expanding the Toolbox of Adoptive Cell Immunotherapy Nasheed M. Hossain , MD1xNasheed M. HossainSearch for articles by this author and Patrick J. Stiff , MD1xPatrick J. StiffSearch for articles by this author Show More 1Division of Hematology-Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, IL https://doi.org/10.1200/JCO.21.00295 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTExpanding the Toolbox of Adoptive Cell ImmunotherapyThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Patrick J. StiffConsulting or Advisory Role: CRSPR Therapeutics AGResearch Funding: Kite Pharma, Seattle Genetics, Gamida Cell, Incyte, Amgen, TG Therapeutics, Macrogenics, Actinium Pharmaceuticals, Atara Biotherapeutics, TakedaNo other potential conflicts of interest were reported. Companion T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects
Case of Antiplakin Dermatosis
Authors: Naoki Oiso, Shigeto Yanagihara, Chiharu Tateishi, Norito Ishii, Takashi Hashimoto, Daisuke Tsuruta, Akira Kawada
Journal: JAMA Dermatology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy
Authors: Szu-Jung Chen, Li-Hsien Chen, Yu-Min Yeh, Chou-Ching K Lin, Peng-Chan Lin, Han-Wei Huang, Meng-Ru Shen, Bo-Wen Lin, Jeng-Chang Lee, Cheng-Che Lee, Yueh-Feng Lee, Huai-Chueh Chiang, Jang-Yang Chang
Journal: Theranostics (2021)

Rationale: Oxaliplatin-induced peripheral neuropathy (OIPN) is a common adverse effect that causes delayed treatment and poor prognosis among colorectal cancer (CRC) patients. However, its mechanism remains elusive, and no effective treatment is available. Methods: We employed a prospective cohort study of adult patients with pathologically confirmed stage III CRC receiving adjuvant chemotherapy with an oxaliplatin-based regimen for investigating OIPN. To further validate the clinical manifestations and identify a potential therapeutic strategy, animal models, and in vitro studies on the mechanism of OIPN were applied. Results: Our work found that (1) consistent with clinical findings, OIPN was observed in animal models. Targeting the enzymatic activity of cathepsin S (CTSS) by pharmacological blockade and gene deficiency strategy alleviates the manifestations of OIPN. (2) Oxaliplatin treatment increases CTSS expression by enhancing cytosol translocation of interferon response factor 1 (IRF1), which then facilitates STIM-dependent store-operated Ca2+ entry homeostasis. (3) The cytokine array demonstrated an increase in anti-inflammatory cytokines and suppression of proinflammatory cytokines in mice treated with RJW-58. (4) Mechanistically, inhibiting CTSS facilitated olfactory receptors transcription factor 1 release from P300/CBP binding, which enhanced binding to the interleukin-10 (IL-10) promoter region, driving IL-10 downstream signaling pathway. (5) Serum CTSS expression is increased in CRC patients with oxaliplatin-induced neurotoxicity. Conclusions: We highlighted the critical role of CTSS in OIPN, which provides a therapeutic strategy for the common adverse side effects of oxaliplatin.
Deficiency of telomere-associated repressor activator protein 1 precipitates cardiac aging in mice <i>via</i> p53/PPARα signaling
Authors: Yin Cai, Hao Liu, Erfei Song, Lin Wang, Jindong Xu, Yi He, Dengwen Zhang, Liyan Zhang, Kenneth King-yip Cheng, Leigang Jin, Min Wu, Shiming Liu, Dake Qi, Liangqing Zhang, Gary D. Lopaschuk, Sheng Wang, Aimin Xu, Zhengyuan Xia
Journal: Theranostics (2021)

Background: Telomere shortening and dysfunction may cause metabolic disorders, tissue damage and age-dependent pathologies. However, little is known about the association of telomere-associated protein Rap1 with mitochondrial energy metabolism and cardiac aging. Methods: Echocardiography was performed to detect cardiac structure and function in Rap1+/+ and Rap1-/- mice at different ages (3 months, 12 months and 20 months). Telomere length, DNA damage, cardiac senescence and cardiomyocyte size were analyzed using the real-time PCR, Western blotting, senescence associated β-galactosidase assay and wheat germ agglutinin staining, respectively. Western blotting was also used to determine the level of cardiac fatty acid metabolism related key enzymes in mouse and human myocardium. Chromatin immunoprecipitation assay was used to verify the direct link between p53 and PPARα. The p53 inhibitor, Pifithrin-α and PPARα activator WY14643 were utilized to identify the effects of Rap1/p53/PPARα signaling pathway. Results: Telomere was shortened concomitant with extensive DNA damage in aged Rap1-/- mouse hearts, evidenced by reduced T/S ratios and increased nuclear γH2AX. Meanwhile, the aging-associated phenotypes were pronounced as reflected by altered mitochondrial ultrastructure, enhanced senescence, cardiac hypertrophy and dysfunction. Mechanistically, acetylated p53 and nuclear p53 was enhanced in the Rap1-/- mouse hearts, concomitant with reduced PPARα. Importantly, p53 directly binds to the promoter of PPARα in mouse hearts and suppresses the transcription of PPARα. In addition, aged Rap1-/- mice exhibited reduced cardiac fatty acid metabolism. Pifithrin-α alleviated cardiac aging and enhanced fatty acid metabolism in the aged Rap1-/- mice. Activating PPARα with WY14643 in primarily cultured Rap1-/- cardiomyocytes restored maximal oxygen consumption rates. Reduced Rap1 expression and impaired p53/PPARα signaling also presented in aged human myocardium. Conclusion: In summary, Rap1 may link telomere biology to fatty acid metabolism and aging-related cardiac pathologies via modulating the p53/PPARα signaling pathway, which could represent a therapeutic target in preventing/attenuating cardiac aging.